Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Report
Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Report
复制标题
来那度胺 (LMID) 显着提高难治性/复发性实体瘤儿童的循环血清 IL-2 和 IL-15 水平、NK 扩增和激活以及 NK 和 LAK 细胞毒性：儿童肿瘤学组 I 期联合报告
DOI：
10.1182/blood.v112.11.107.107
复制
发表时间：
2008
期刊：
影响因子：
20.3
通讯作者：
M. Cairo
中科院分区：
文献类型：
--
作者：
J. Ayello;S. Berg;M. Krailo;C. Ven;A. Ingle;D. Lewis;L. Harrison;S. Blaney;P. Adamson;M. Cairo
